Primary Topics of Discussion

  • Most efficient regulatory approval process for FIH trials – DOs & DONTs.
  • Nitty Gritty; sample management and logistics to and from Australia.
  • 43.5% R&D cash back: can be applicable to your entire IND-enabling GLP Toxicology package.
  • Human Research Ethics Committee (HREC) requirements on nonclinical data.
  • How Australia’s world class nonclinical through clinical research infrastructure supports early phase clinical research studies with speed, quality, and cost advantages.

Expert Panelists